Communiqués Repare Therapeutics Inc.

Actions

RPTX

US7602731025

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 31/05/2024			Varia. 5j.	Varia. 1 janv.
3,48 ^USD	+3,88 %		+11,54 %	-52,33 %

08/05	Les plus fortes hausses du prémarché	MT
07/05	Repare Therapeutics Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI

Communiqués

Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !

Inscription 100% Gratuite

Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024	29/05	BU
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial Results	07/05	BU
DEBIOPHARM AND REPARE THERAPEUTICS ANNOUNCE FIRST PATIENT DOSED IN PHASE 1/1B MYTHIC TRIAL EVALUATING THE SYNTHETIC LETHAL COMBINATION OF WEE1 AND PKMYT1 INHIBITION	01/05	AQ
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 Inhibition	30/04	BU
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition	30/04	BU
DEBIOPHARM ET REPARE THERAPEUTICS ANNONCENT LE TRAITEMENT D’UN PREMIER PATIENT DANS LE CADRE DE L’ÉTUDE DE PHASE 1/1B MYTHIC ÉVALUANT LA COMBINATION D’INHIBITEURS WEE1 ET PKMYT1 GÉNÉRANT UNE LÉTHALITÉ SYNTHÉTIQUE	30/04	BU
Repare Therapeutics Appoints Steven H. Stein, M.D. to its Board of Directors	26/04	BU
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	21/03	BU
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	15/03	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	12/03	PR
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	03/03	PR
Repare Therapeutics to Participate in Two Upcoming Investor Conferences	29/02	BU
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	28/02	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	24/02	PR
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)	17/02	BU
Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTX	16/02	PR
Repare Therapeutics Doses First Patient in Phase 1 Clinical Trial of RP-1664	15/02	BU
Repare Therapeutics to Regain Global Rights to Camonsertib	12/02	BU
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment	25/01	BU
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones	08/01	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Repare Therapeutics Inc.

Actions

RPTX

US7602731025

Communiqués

Filtres